Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.

Détails

ID Serval
serval:BIB_2BC44A699A59
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
Périodique
Clinical genitourinary cancer
Auteur(s)
Sandmeier N., Rothschild S.I., Rothermundt C., Cathomas R., Schardt J., Berthold D., von Burg P., Müller B., Beyer J., Vogt D.R., Stenner F.
ISSN
1938-0682 (Electronic)
ISSN-L
1558-7673
Statut éditorial
Publié
Date de publication
08/2018
Peer-reviewed
Oui
Volume
16
Numéro
4
Pages
e711-e718
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
In metastatic renal-cell carcinoma (mRCC), physicians have a plethora of therapeutic choices, with the latest addition of checkpoint inhibitors. However, many questions regarding the best use of the respective drugs remain unanswered. Therefore, it is important to examine and summarize the outcome of real-world experiences to understand the practical value of the various drugs in daily use and foster optimal treatment algorithms for patients with renal-cell carcinoma. We sought to describe the pattern of care in mRCC under circumstances with access to all therapeutic options for patients.
We examined the outcome of patients with mRCC who were treated at 8 major centers in Switzerland, mainly with vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibitors. Data from 110 patients with mRCC who had undergone more than one systemic therapy were collected and analyzed. We assessed the pattern of care for patients with mRCC in an unrestricted health care system and outcomes with regard to the respective treatment sequences. We also studied the compliance of individual therapies with published guidelines and correlated the adherence to outcome. Finally, immediate versus deferred treatment and the number of received therapeutic drug lines were analyzed.
Median survival of patients treated with targeted agents for mRCC was 2.0 years.
Exposure to more than 2 lines of systemic drugs did not improve outcome of patients with mRCC.
Mots-clé
Algorithms, Antineoplastic Agents/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/surgery, Delivery of Health Care/methods, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/surgery, Male, Middle Aged, Molecular Targeted Therapy/methods, Neoplasm Metastasis, Patient Outcome Assessment, Retrospective Studies, Survival Analysis, Switzerland, Treatment Outcome, Sequential therapy in mRCC, Swiss mRCC cohort, Tyrosine kinase inhibitor (TKI), VEGF-targeted therapy, mTOR inhibitors
Pubmed
Web of science
Création de la notice
10/03/2018 10:49
Dernière modification de la notice
26/03/2019 7:26
Données d'usage